瑞博生物-B(06938)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06938 瑞博生物-B

未开盘 07-08 16:08:17

55.600

+3.700

+7.13%

最高55.950	最低51.600	成交量31.34万
今开52.900	昨收51.900	日振幅8.38%
总市值94.83亿	流通市值94.83亿	总股本1.71亿
成交额1,703万	换手率0.18%	流通股本1.71亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06938","market":"HK","secType":"STK","nameCN":"瑞博生物-B","latestPrice":55.6,"timestamp":1783498097917,"preClose":51.9,"halted":0,"volume":313400,"delay":0,"changeRate":0.07129094412331412,"floatShares":170554910,"shares":170554910,"eps":-2.100221,"marketStatus":"未开盘","change":3.7,"latestTime":"07-08 16:08:17","open":52.9,"high":55.95,"low":51.6,"amount":17031830,"amplitude":0.083815,"askPrice":55.6,"askSize":5600,"bidPrice":55.3,"bidSize":200,"shortable":0,"etf":0,"ttmEps":-1.805,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1783560600000},"marketStatusCode":0,"adr":0,"listingDate":1767888000000,"exchange":"SEHK","adjPreClose":51.9,"openAndCloseTimeList":[[1783474200000,1783483200000],[1783486800000,1783497600000]],"volumeRatio":1.042484,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06938","defaultTab":"news","newsList":[{"id":"1100105146","title":"瑞博生物-B更新2026年6月股份变动月报表，股本保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1100105146","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100105146?lang=zh_cn&edition=full","pubTime":"2026-07-07 17:14","pubTimestamp":1783415681,"startTime":"0","endTime":"0","summary":"苏州瑞博生物技术股份有限公司于2026年7月7日发布截至2026年6月30日的股份变动月报表。报告显示，公司法定注册股本及已发行股份在6月期间保持不变，注册股本为人民币170,554,910元，已发行股份总数为170,554,910股，未有新增发行或回购注销活动。报告还披露，截至本月末，公司共有2,113,987份尚未行使的股份期权，行使价为每股人民币3.70元，最早归属日期为2028年1月9日。本次月报由联席公司秘书张甦签署，表明公司在报告期内的股份变动及信息披露合法合规。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101410481","title":"瑞博生物-B联席CEO增持公司13,200股H股","url":"https://stock-news.laohu8.com/highlight/detail?id=1101410481","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101410481?lang=zh_cn&edition=full","pubTime":"2026-07-07 16:55","pubTimestamp":1783414511,"startTime":"0","endTime":"0","summary":"7月3日，瑞博生物-B（06938.HK）发布公告称，公司联席首席执行官于近期购入了13,200股公司H股股份。此次增持行为体现了管理层对公司未来发展的信心。公司后续相关动态将持续受到市场关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649121605","title":"中邮证券：首予瑞博生物(06938.HK)“买入”评级 静待肝外递送平台突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2649121605","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649121605?lang=zh_cn&edition=full","pubTime":"2026-07-07 11:18","pubTimestamp":1783394304,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649610057","title":"招商证券国际： 新增瑞博生物(06938.HK)为首选股之一 目标价105港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2649610057","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649610057?lang=zh_cn&edition=full","pubTime":"2026-07-06 11:20","pubTimestamp":1783308007,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1564","BK1147","06938","BK1161","06099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648668995","title":"瑞博生物-B(06938.HK)获执行董事甘黎明增持1.32万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2648668995","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648668995?lang=zh_cn&edition=full","pubTime":"2026-07-03 18:22","pubTimestamp":1783074148,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648576543","title":"港股异动 | 瑞博生物-B(06938)午前涨超6% 与Madrigal在siRNA合作项目的首个里程碑达成","url":"https://stock-news.laohu8.com/highlight/detail?id=2648576543","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648576543?lang=zh_cn&edition=full","pubTime":"2026-07-02 11:45","pubTimestamp":1782963941,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，瑞博生物-B午前涨超6%，截至发稿，涨5.49%，报11.33港元，成交额1738.45万港元。消息面上，7月2日，瑞博生物-B发布公告，本公司与Madrigal在siRNA合作项目中，首个候选药物选定里程碑已经达成，本次合作旨在推动针对肝脏疾病的尖端RNA疗法，主要专注于代谢功能障碍相关脂肪性肝炎。本公司与Madrigal旨在利用本公司经验证的肝脏靶向RiboGalSTARTM平台开发前景广阔的siRNA药物，为存在庞大医疗需求的MASH患者提供更具针对性及更有效的治疗方案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1462188.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK1161","BK4588","VXUS","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648605527","title":"瑞博生物-B(06938)与MADRIGAL合作的首个里程碑达成","url":"https://stock-news.laohu8.com/highlight/detail?id=2648605527","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648605527?lang=zh_cn&edition=full","pubTime":"2026-07-02 08:20","pubTimestamp":1782951607,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞博生物-B 发布公告，本公司与Madrigal在siRNA合作项目中，首个候选药物选定里程碑已经达成，本次合作旨在推动针对肝脏疾病的尖端RNA疗法，主要专注于代谢功能障碍相关脂肪性肝炎。此里程碑为双方高效协作的成果，其后将随即启动新药临床试验申请支持性研究，以支持后续的临床研究。本公司与Madrigal旨在利用本公司经验证的肝脏靶向RiboGalSTARTM平台开发前景广阔的siRNA药物，为存在庞大医疗需求的MASH患者提供更具针对性及更有效的治疗方案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1462082.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647453054","title":"55家公司港股通新贵即将喜迎北水流入 入通门槛或已抬升至102.67亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2647453054","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647453054?lang=zh_cn&edition=full","pubTime":"2026-07-01 10:09","pubTimestamp":1782871774,"startTime":"0","endTime":"0","summary":"核心规则：市值门槛动态调整截至2026年6月30日，港股通实际纳入门槛已升至102.67亿，剔除门槛达66.89亿。这一指标直接决定了个股在指数中的权重与港股通资格。对于不同上市时长的公司，要求有所不同：对于上市公司而言，维持日均万五左右的换手率是保住港股通资格的关键。数据截止日为每年的6月30日和12月31日，这也是上市公司\"冲关\"港股通的关键时间窗口。","market":"hk","thumbnail":"https://static.tigerbbs.com/0cf777090175126e4590c3b8afdfe41e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/0cf777090175126e4590c3b8afdfe41e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1461288.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["02670","02726","BK4585","01511","02672","07630","02696","06675","00068","00340","03310","02272","03625","01236","02553","06656","02335","BK4588","01191","03355","01021","01392","01956","02616","02723","01286","06872","09630","00863","01866","03388","02526","07666","01609","01133","00376","06106","01081","02142","06938","03887","01651","00600","03661","07688","02632","06658","01779","03277","02729","09637","06636","00100","00412","01440","01672","01879"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2647552785","title":"瑞博生物-B(06938)拟收购兴博润25.93%股权 持股增至约88.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2647552785","media":"智通财经网","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647552785?lang=zh_cn&edition=full","pubTime":"2026-06-30 22:38","pubTimestamp":1782830320,"startTime":"0","endTime":"0","summary":"根据增资协议，海河凯莱英基金获授予赎回权，使其有权于发生约定赎回事件时要求赎回其于兴博润的股权。于收购事项完成后，本公司于兴博润的股权将由约62.24%增至约88.17%，从而加强本公司对兴博润的控制权，并使本公司有权获得兴博润产生的更大份额经济利益及未来回报。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1461617.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"瑞博生物-B(06938)拟收购兴博润25.93%股权 持股增至约88.17%","news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647582260","title":"【券商聚焦】群益证券予瑞博生物-B(06938)“买进”评级 看好其小核酸药物管线价值兑现","url":"https://stock-news.laohu8.com/highlight/detail?id=2647582260","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647582260?lang=zh_cn&edition=full","pubTime":"2026-06-30 13:57","pubTimestamp":1782799072,"startTime":"0","endTime":"0","summary":"公司尚未有产品商业化，2025年营收1.5亿元人民币，同比增长4%，主要来自勃林格殷格翰的里程碑付款及核苷酸单体销售；同期实际亏损2.8亿元，因多个管线处于临床期，研发支出较大。财务预测方面，该机构预计公司2026至2028年净利润分别为-0.1亿、-2.8亿及-2.8亿元人民币。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/MjZhZmU5OWE5M2M5YjFiNzE1NDI2Mjg5NzQxNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjZhZmU5OWE5M2M5YjFiNzE1NDI2Mjg5NzQxNQ==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984843","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645041242","title":"招商证券：首予瑞博生物(06938)“增持”评级 目标价105港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2645041242","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645041242?lang=zh_cn&edition=full","pubTime":"2026-06-22 15:12","pubTimestamp":1782112337,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，招商证券国际发布研究报告称，首次给予瑞博生物(06938)“增持”评级，目标价105港元，看好其核心资产RBD4059为全球首个靶向凝血因子XI的小干扰核酸(siRNA)抗凝药，有望成为新一代长效抗凝疗法。报告指出，全球抗凝药市场未来容量有望达600亿美元，拜耳旗下Asundexian是全球首款针对凝血因子XIa的小分子，已于5月提交美国FDA上市申请，预计年底上市，预料将重塑全球抗凝药格局。招商证券国际目前预计瑞博生物2026至2028年收入分别为4.42亿、1.15亿及1.47亿元人民币，预测录年度亏损2.88亿、3,800万及3.35亿元人民币。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456823.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06099","EWH","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641310203","title":"瑞博生物-B(06938)拟动用至多1亿元回购公司H股","url":"https://stock-news.laohu8.com/highlight/detail?id=2641310203","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641310203?lang=zh_cn&edition=full","pubTime":"2026-06-08 16:37","pubTimestamp":1780907831,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞博生物-B 发布公告，本公司拟动用至多人民币1亿元的内部资金，供本公司委任的专业受托人于自本公告日期起十二个月内根据本公司H股股份激励计划，透过市场上交易及╱或其他符合H股股份激励计划及适用法律法规的许可方式，按董事会不时厘定的时间及频次购买本公司H股。股份回购拟动用至多人民币1亿元用于购回H股。本公司拟将回购的H股持作库存股份。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451376.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"瑞博生物-B(06938)拟动用至多1亿元回购公司H股","news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154233652","title":"瑞博生物-B2026年5月股份变动月报，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1154233652","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154233652?lang=zh_cn&edition=full","pubTime":"2026-06-04 17:50","pubTimestamp":1780566654,"startTime":"0","endTime":"0","summary":"苏州瑞博生物技术股份有限公司于2026年6月4日发布的截至2026年5月31日止月份证券变动月报表显示，其股本结构在本月维持稳定，已发行股份总数仍为170,554,910股，注册股本为人民币170,554,910元，全部为H股，票面价值为人民币1元。截至本月底，库藏股份数量依旧为0。报告期内，瑞博生物-B未进行新增股份发行、未发生回购、注销或库藏股变动，已发行股份数与库藏股份数均无变化。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104647122","title":"瑞博生物宣布向EMA提交II期临床试验申请，其siRNA疗法于血栓栓塞性疾病领域再获进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1104647122","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104647122?lang=zh_cn&edition=full","pubTime":"2026-05-28 10:52","pubTimestamp":1779936731,"startTime":"0","endTime":"0","summary":"瑞博生物-B宣布，已就其在研的siRNA疗法向欧洲药品管理局提交了II期临床试验申请。此举标志着该公司在血栓栓塞性疾病治疗领域的研发进程取得了重要推进。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638234632","title":"瑞博生物-B(06938)提交RBD1119注射液用于治疗冠状动脉疾病的II期临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2638234632","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638234632?lang=zh_cn&edition=full","pubTime":"2026-05-28 07:46","pubTimestamp":1779925602,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞博生物-B 发布公告，已成功向欧洲药品管理局提交本公司自主研发产品RBD1119注射液用于治疗冠状动脉疾病的II期临床试验申请。尽管标准治疗已被广泛使用，但即使在最佳化治疗下，稳定型CAD患者仍面临发生血栓事件的较大残余风险。RBD1119注射液为一种新型抗血栓siRNA疗法，能提供有效及持久的血栓防护，同时保持良好的安全性特征，尤其是在出血风险方面。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446941.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"瑞博生物-B(06938)提交RBD1119注射液用于治疗冠状动脉疾病的II期临床试验申请","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636181634","title":"东吴证券：维持瑞博生物-B(06938)“买入”评级 肝外技术多项突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2636181634","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636181634?lang=zh_cn&edition=full","pubTime":"2026-05-20 14:19","pubTimestamp":1779257985,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，东吴证券发布研报称，瑞博生物-B当前收入主要来自合作授权的里程碑付款，现阶段已有4款候选药物进入临床2期阶段，假设于2030年获批上市并开始贡献销售收入，并假设与合作伙伴达成50%:50%分成比例。采用FCFF法对公司进行估值，最终模型目标价为100.7元人民币/115.8元港币，对比当前股价57.95港元，仍有较大空间，维持“买入”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443860.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["601555","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636304327","title":"“2026智通财经夏季路演大会”活动报名中 ！","url":"https://stock-news.laohu8.com/highlight/detail?id=2636304327","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636304327?lang=zh_cn&edition=full","pubTime":"2026-05-18 10:06","pubTimestamp":1779069961,"startTime":"0","endTime":"0","summary":"5月28日，深圳前海。40+港股上市公司集中路演，与机构及高净值投资者面对面交流。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20260518/20260518102433_43763.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260518/20260518102433_43763.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442727.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["02659","LU0307460666.USD","01384","02411","02650","01333","03858","02706","02652","02623","02889","02675","02729","01396","HK0001040143.USD","BK1100","01907","06090","06682","06051","02670","03317","02526","03881","00363","06636","02142","BK1155","01378","00400","01300","06651","00305","02726","00290","LU0287142896.SGD","01021","00826","02565","02228","08299","09696","02655","06938","02685","00650","BK1171","LU0314109678.HKD","VXUS","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119656495","title":"瑞博生物宣布与英矽智能达成战略合作，加速AI驱动的小干扰RNA药物研发","url":"https://stock-news.laohu8.com/highlight/detail?id=1119656495","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119656495?lang=zh_cn&edition=full","pubTime":"2026-05-12 20:31","pubTimestamp":1778589071,"startTime":"0","endTime":"0","summary":"瑞博生物-B（RIBOLIFE-B）与英矽智能（Insilico Medicine）宣布达成一项战略合作，旨在利用人工智能技术加速小干扰RNA（siRNA）药物的研发进程。此次合作将结合双方在生物技术与人工智能领域的专长，共同探索和开发创新疗法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109317054","title":"瑞博生物-B获董事会授权拟回购不超过已发行股份10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1109317054","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109317054?lang=zh_cn&edition=full","pubTime":"2026-05-12 17:51","pubTimestamp":1778579519,"startTime":"0","endTime":"0","summary":"苏州瑞博生物技术股份有限公司于最新公告中披露，将在2026年6月5日召开的股东周年大会上提请特别决议案，授权公司董事于法定期间内回购不超过已发行H股总数的10%。公司H股总数为170,554,910股，若该授权通过，最多回购股数可达17,055,491股。自2026年1月9日公司在香港联合交易所有限公司上市以来，瑞博生物-B股价曾在2026年1月至5月间最高达每股95.80港元、最低报51.20港元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"瑞博生物-B获董事会授权拟回购不超过已发行股份10%","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634240264","title":"瑞博生物-B(06938)：核心产品VORTOSIRAN完成针对静脉血栓栓塞适应症的2b期临床试验申请递交","url":"https://stock-news.laohu8.com/highlight/detail?id=2634240264","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634240264?lang=zh_cn&edition=full","pubTime":"2026-05-11 17:42","pubTimestamp":1778492557,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞博生物-B 发布公告，本公司核心产品vortosiran 已成功向欧洲药品管理局递交针对静脉血栓栓塞症防治的 2b期临床试验申请。本研究为本公司涵盖多个已规划的针对多种血栓栓塞性心血管适应症的2b期研究的一部分。Vortosiran是全球进展最快的靶向FXI的小核酸药物，及截至本公告日期，该产品已完成针对冠状动脉疾病的欧洲2a期临床试验，且其针对心房颤动的 2b期CTA已于2026年4月向EMA递交。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440240.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ribolia.com","stockEarnings":[{"period":"1week","weight":0.1855},{"period":"1month","weight":0.0713},{"period":"3month","weight":-0.1924},{"period":"6month","weight":-0.3228},{"period":"ytd","weight":-0.0409}],"compareEarnings":[{"period":"1week","weight":0.0576},{"period":"1month","weight":-0.0186},{"period":"3month","weight":-0.0603},{"period":"6month","weight":-0.0775},{"period":"1year","weight":0.0021},{"period":"ytd","weight":-0.0558}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"苏州瑞博生物技术股份有限公司是一家主要从事小核酸药物研究和开发，尤其专注于小干扰核酸（siRNA）疗法的中国公司。该公司的主营业务是从事小核酸药物的创新，专注于心血管、代谢类、肾脏和肝病以及其他治疗领域。该公司的药物管线包括RBD4059、RBD5044、RBD7022、RBD7007、RBD2080、RBD1119、RBD1016等。该公司主要在中国国内市场开展业务。","exchange":"SEHK","name":"瑞博生物-B","nameEN":"RIBOLIFE-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"瑞博生物-B(06938)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供瑞博生物-B(06938)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"瑞博生物-B,06938,瑞博生物-B股票,瑞博生物-B股票老虎,瑞博生物-B股票老虎国际,瑞博生物-B行情,瑞博生物-B股票行情,瑞博生物-B股价,瑞博生物-B股市,瑞博生物-B股票价格,瑞博生物-B股票交易,瑞博生物-B股票购买,瑞博生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"瑞博生物-B(06938)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供瑞博生物-B(06938)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}